Together with the precedents of the therapeutic effectiveness of an ADC against CD98hc in triple negative breast cancer, the finding CD98hc was differentially expressed in CRC when compared to normal colon tissue, represented an attractive setting in which to explore whether an anti-CD98hc ADC could be efficacious in colon cancer. The gene discussed is SLC3A2; the disease is colonic neoplasm.